ACA
XBI icon

Ascension Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ascension Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,158
Closed -$1.12M – 86
2025
Q4 		$1.12M Buy
+9,158
New +$1.05M 0.38% 27

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ascension Capital Advisors's XBI Position: Q1 2026 in Review

Ascension Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 9,158 shares — an estimated $1.12M sold.

Ascension Capital Advisors first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $1.12M in Q4 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Ascension Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Ascension Capital Advisors sold 9,158 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.12M.
  • Ascension Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Ascension Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $1.12M in Q4 2025.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Ascension Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.